Last reviewed · How we verify
Injection, placebo of toxin + corticoid
Injection, placebo of toxin + corticoid is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development.
This is a placebo injection combining an inactivated toxin with a corticosteroid, designed to test the efficacy and safety of toxin-based immunotherapy with anti-inflammatory corticoid co-administration.
At a glance
| Generic name | Injection, placebo of toxin + corticoid |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The drug formulation pairs a detoxified or neutralized toxin (likely intended to trigger a controlled immune response) with a corticosteroid to modulate inflammation. This combination is being evaluated in Phase 3 trials, suggesting investigation of whether the corticoid can enhance tolerability or efficacy of toxin-based immunotherapy while managing inflammatory side effects.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injection, placebo of toxin + corticoid CI brief — competitive landscape report
- Injection, placebo of toxin + corticoid updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI